These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 25609219

  • 1. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.
    Djebli N, Fabre D, Boulenc X, Fabre G, Sultan E, Hurbin F.
    Drug Metab Dispos; 2015 Apr; 43(4):510-22. PubMed ID: 25609219
    [Abstract] [Full Text] [Related]

  • 2. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
    Wang XQ, Shen CL, Wang BN, Huang XH, Hu ZL, Li J.
    Gene; 2015 Mar 10; 558(2):200-7. PubMed ID: 25542807
    [Abstract] [Full Text] [Related]

  • 3. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
    Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, Dubar M.
    Clin Pharmacol Ther; 2011 Aug 10; 90(2):287-95. PubMed ID: 21716274
    [Abstract] [Full Text] [Related]

  • 4. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
    Kobayashi M, Kajiwara M, Hasegawa S.
    J Atheroscler Thromb; 2015 Aug 10; 22(11):1186-96. PubMed ID: 26063503
    [Abstract] [Full Text] [Related]

  • 5. Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite.
    Boulenc X, Djebli N, Shi J, Perrin L, Brian W, Van Horn R, Hurbin F.
    Drug Metab Dispos; 2012 Jan 10; 40(1):187-97. PubMed ID: 22004687
    [Abstract] [Full Text] [Related]

  • 6. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
    Pedersen RS, Nielsen F, Stage TB, Vinholt PJ, el Achwah AB, Damkier P, Brosen K.
    Clin Exp Pharmacol Physiol; 2014 Nov 10; 41(11):870-8. PubMed ID: 25115434
    [Abstract] [Full Text] [Related]

  • 7. The influence of genetic polymorphism of Cyp2c19 isoenzyme on the pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases.
    Karaźniewicz-Łada M, Danielak D, Rubiś B, Burchardt P, Oszkinis G, Główka F.
    J Clin Pharmacol; 2014 Aug 10; 54(8):874-80. PubMed ID: 24782221
    [Abstract] [Full Text] [Related]

  • 8. The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes.
    Kim HS, Lim Y, Oh M, Ghim JL, Kim EY, Kim DH, Shin JG.
    Br J Clin Pharmacol; 2016 Feb 10; 81(2):301-12. PubMed ID: 26426352
    [Abstract] [Full Text] [Related]

  • 9. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.
    Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, Sugiyama D, DeGorter MK, Woolsey S, Tirona RG, Kim RB.
    Eur Heart J; 2012 Nov 10; 33(22):2856-2464a. PubMed ID: 22374717
    [Abstract] [Full Text] [Related]

  • 10. Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men.
    Hurbin F, Boulenc X, Daskalakis N, Farenc C, Taylor T, Bonneau D, Lacreta F, Cheng S, Sultan E.
    J Clin Pharmacol; 2012 Oct 10; 52(10):1506-15. PubMed ID: 22128201
    [Abstract] [Full Text] [Related]

  • 11. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, Scott SA, Montalescot G.
    Circ Cardiovasc Interv; 2011 Oct 01; 4(5):422-8. PubMed ID: 21972404
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.
    Horenstein RB, Madabushi R, Zineh I, Yerges-Armstrong LM, Peer CJ, Schuck RN, Figg WD, Shuldiner AR, Pacanowski MA.
    J Clin Pharmacol; 2014 Aug 01; 54(8):865-73. PubMed ID: 24710841
    [Abstract] [Full Text] [Related]

  • 13. A physiologically based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: An evaluation of CYP2C19 activity.
    Duong JK, Nand RA, Patel A, Della Pasqua O, Gross AS.
    Pharmacol Res Perspect; 2022 Apr 01; 10(2):e00946. PubMed ID: 35307978
    [Abstract] [Full Text] [Related]

  • 14. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
    Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS, Brandt JT, Darstein C, Jakubowski JA, Salazar DE.
    Clin Pharmacol Ther; 2007 May 01; 81(5):735-41. PubMed ID: 17361128
    [Abstract] [Full Text] [Related]

  • 15. The Metabolism of Clopidogrel: CYP2C19 Is a Minor Pathway.
    Ford NF.
    J Clin Pharmacol; 2016 Dec 01; 56(12):1474-1483. PubMed ID: 27196064
    [Abstract] [Full Text] [Related]

  • 16. Differential impact of selective serotonin reuptake inhibitors on platelet response to clopidogrel: a randomized, double-blind, crossover trial.
    Hirsh-Rokach B, Spectre G, Shai E, Lotan A, Ritter A, Al-Aieshy F, Malmström RE, Varon D, Alcalai R.
    Pharmacotherapy; 2015 Feb 01; 35(2):140-7. PubMed ID: 25689244
    [Abstract] [Full Text] [Related]

  • 17. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD.
    J Am Coll Cardiol; 2013 Feb 26; 61(8):872-9. PubMed ID: 23333143
    [Abstract] [Full Text] [Related]

  • 18. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).
    Collet JP, Hulot JS, Anzaha G, Pena A, Chastre T, Caron C, Silvain J, Cayla G, Bellemain-Appaix A, Vignalou JB, Galier S, Barthélémy O, Beygui F, Gallois V, Montalescot G, CLOVIS-2 Investigators.
    JACC Cardiovasc Interv; 2011 Apr 26; 4(4):392-402. PubMed ID: 21511218
    [Abstract] [Full Text] [Related]

  • 19. Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype.
    Chiang M, Sychterz C, Perera V, Merali S, Palmisano M, Templeton IE, Gaohua L.
    Clin Pharmacol Ther; 2023 Oct 26; 114(4):922-932. PubMed ID: 37467157
    [Abstract] [Full Text] [Related]

  • 20. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
    Gurbel PA, Bergmeijer TO, Tantry US, ten Berg JM, Angiolillo DJ, James S, Lindahl TL, Svensson P, Jakubowski JA, Brown PB, Duvvuru S, Sundseth S, Walker JR, Small D, Moser BA, Winters KJ, Erlinge D.
    Thromb Haemost; 2014 Sep 02; 112(3):589-97. PubMed ID: 25008027
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.